# Antibody and Reagent Development Core

> **NIH NIH P01** · WASHINGTON UNIVERSITY · 2024 · $538,562

## Abstract

Core B - Project Summary/Abstract
Filoviruses, which are NIAID category A priority pathogens, can subvert host immune systems to facilitate viral
replication, resulting in human case fatality rates as high as 90%. The filoviral genome encodes for seven to nine
proteins. Despite the small number of genes, limited information is available on the specific mechanisms by
which different viral-viral and viral-host interactions contribute to filoviral replication and pathogenesis, hindering
the development of antivirals or vaccines. The Antibody and Reagent Development Core (Core B) will provide
critical reagents and support for the overall scientific mission and facilitate the characterization of these
interactions. Specifically, Core B will provide a unique set of standardized antibodies, cell-lines, and mouse
models that will be disseminated amongst the Research Projects (RPs) and Cores of the PPG. In consultation
with the Administrative Core (Core A) and the PPG leadership, Core B will prioritize experiments to ensure that
reagents will be readily available to the RPs and Cores for use, validation, and characterization of interfaces
between viral proteins and host factors that impact steps in the filoviral replication cycle. Core B will develop
mouse monoclonal and synthetic antibodies against Ebola and Marburg viral proteins, generate knockout cell
lines of host factors, and generate conditional knockout mouse models of select host factors identified by RP01,
RP02, RP03, and Core C when such reagents are not commercially available. Given the need for a unified
reagent development pipeline, the scientific core activity for Core B is justified.

## Key facts

- **NIH application ID:** 10904616
- **Project number:** 5P01AI120943-07
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Daisy W Leung
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $538,562
- **Award type:** 5
- **Project period:** 2016-07-07 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10904616

## Citation

> US National Institutes of Health, RePORTER application 10904616, Antibody and Reagent Development Core (5P01AI120943-07). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10904616. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*